Quantification of anidulafungin and micafungin in human body fluids by high performance-liquid chromatography with UV-detection.


Journal

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences
ISSN: 1873-376X
Titre abrégé: J Chromatogr B Analyt Technol Biomed Life Sci
Pays: Netherlands
ID NLM: 101139554

Informations de publication

Date de publication:
15 Feb 2020
Historique:
received: 16 09 2019
revised: 03 12 2019
accepted: 10 12 2019
pubmed: 21 1 2020
medline: 21 4 2020
entrez: 21 1 2020
Statut: ppublish

Résumé

The echinocandins anidulafungin (ANID) and micafungin (MICA) are recommended for treatment of invasive Candida infections. As target-site concentrations of antimicrobial agents are crucial for eradication of pathogens, we established and validated high-performance liquid chromatography-UV detection (HPLC-UV) assays for quantification of ANID and MICA in human plasma, ascites fluid, pleural effusion, and in cerebrospinal fluid (CSF). Sample pre-purification was performed by protein precipitation with acetonitrile followed by solid phase extraction. For both assays, intra- and interday precision, and accuracy fulfilled the requirements for bioanalytical methods issued by the European Medicine Agency (EMA). The lower limit of quantification was 0.01 mg/L for both drugs. At 25 °C, ANID and MICA concentrations declined by up to 70% within 24 h. Concentrations remained stable over 24 h at 4 °C and over four weeks at -80 °C. In conclusion, the developed methods are fit for the assessment of target-site pharmacokinetics of ANID and MICA in clinical studies.

Identifiants

pubmed: 31958565
pii: S1570-0232(19)31391-1
doi: 10.1016/j.jchromb.2019.121937
pii:
doi:

Substances chimiques

Anidulafungin 9HLM53094I
Micafungin R10H71BSWG

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

121937

Subventions

Organisme : Austrian Science Fund FWF
ID : KLI 565
Pays : Austria

Informations de copyright

Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest R.B. has received an IIR grant from Pfizer, has received honoraria from Basiliea and Merck Sharp & Dohme, and he is a member of an advisory board of Merck Sharp & Dohme. All other authors have no conflict of interest to declare.

Auteurs

René Welte (R)

Clinical Pharmacokinetics Unit, Division of Intensive Care and Emergency Medicine, Department of Internal Medicine I, Medical University of Innsbruck, Innsbruck, Austria.

Herbert Oberacher (H)

Institute of Legal Medicine and Core Facility Metabolomics, Medical University of Innsbruck, Innsbruck, Austria.

Bernhard Schwärzler (B)

Clinical Pharmacokinetics Unit, Division of Intensive Care and Emergency Medicine, Department of Internal Medicine I, Medical University of Innsbruck, Innsbruck, Austria.

Michael Joannidis (M)

Division of Intensive Care and Emergency Medicine, Department of Internal Medicine I, Medical University of Innsbruck, Innsbruck, Austria.

Romuald Bellmann (R)

Clinical Pharmacokinetics Unit, Division of Intensive Care and Emergency Medicine, Department of Internal Medicine I, Medical University of Innsbruck, Innsbruck, Austria. Electronic address: romuald.bellmann@i-med.ac.at.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH